iTeos Therapeutics, Inc.
ITOS
Price:
$11.85
Market Cap:
$432.78M
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachuset...[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
ITOS
The ROE as of September 2024 (TTM) for iTeos Therapeutics, Inc. (ITOS) is -18.19%
According to iTeos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -18.19%. This represents a change of 286.19% compared to the average of -4.71% of the last 4 quarters.
iTeos Therapeutics, Inc. (ITOS) Historical ROE (quarterly & annually)
How has ITOS ROE performed in the past?
The mean historical ROE of iTeos Therapeutics, Inc. over the last ten years is -40.21%. The current -18.19% ROE has changed -54.77% with respect to the historical average. Over the past ten years (40 quarters), ITOS's ROE was at its highest in in the December 2021 quarter at 33.44%. The ROE was at its lowest in in the December 2019 quarter at -34.31%.
Average
-40.21%
Median
-15.67%
Minimum
-143.30%
Maximum
38.80%
iTeos Therapeutics, Inc. (ITOS) ROE by Quarter and Year
Discovering the peaks and valleys of iTeos Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 19.46%
Maximum Annual ROE = 38.80%
Minimum Annual Increase = -429.76%
Minimum Annual ROE = -143.30%
| Year | ROE | Change |
|---|---|---|
| 2023 | -19.58% | -234.39% |
| 2022 | 14.57% | -62.45% |
| 2021 | 38.80% | -429.76% |
| 2020 | -11.77% | -91.79% |
| 2019 | -143.30% | 19.46% |
iTeos Therapeutics, Inc. (ITOS) Average ROE
How has ITOS ROE performed in the past?
The current ROE of iTeos Therapeutics, Inc. (ITOS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
11.26%
5-year avg
-24.26%
10-year avg
-40.21%
iTeos Therapeutics, Inc. (ITOS) ROE vs. Peers
How is ITOS’s ROE compared to its peers?
iTeos Therapeutics, Inc.’s ROE is greater than Icosavax, Inc. (-41.24%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than VectivBio Holding AG (-56.92%), greater than Annexon, Inc. (-44.68%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than TScan Therapeutics, Inc. (-59.83%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than MoonLake Immunotherapeutics (-11.05%), greater than Revolution Medicines, Inc. (-34.57%), greater than Blueprint Medicines Corporation (-85.25%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Kymera Therapeutics, Inc. (-28.88%),
| Company | ROE | Market cap |
|---|---|---|
| -41.24% | $769.04M | |
| -81.10% | $4.12B | |
| -56.92% | $1.06B | |
| -44.68% | $750.14M | |
| -37.20% | $989.87M | |
| -24.51% | $181.50M | |
| -70.40% | $344.30M | |
| -18.48% | $314.24M | |
| -131.94% | $779.71M | |
| -139.02% | $4.36B | |
| -59.83% | $307.25M | |
| -39.58% | $665.01M | |
| -122.70% | $1.21B | |
| -24.63% | $153.20M | |
| -46.15% | $181.10M | |
| -11.05% | $3.21B | |
| -34.57% | $7.39B | |
| -85.25% | $5.44B | |
| -71.60% | $986.64M | |
| -28.88% | $3.10B |
Build a custom stock screener for iTeos Therapeutics, Inc. (ITOS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like iTeos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
iTeos Therapeutics, Inc. (ITOS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like iTeos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is iTeos Therapeutics, Inc.'s ROE?
How is the ROE calculated for iTeos Therapeutics, Inc. (ITOS)?
What is the highest ROE for iTeos Therapeutics, Inc. (ITOS)?
What is the 3-year average ROE for iTeos Therapeutics, Inc. (ITOS)?
What is the 5-year average ROE for iTeos Therapeutics, Inc. (ITOS)?
How does the current ROE for iTeos Therapeutics, Inc. (ITOS) compare to its historical average?